Author | Sumanta K. Pal, MD


ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy

February 19, 2017

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases

June 15, 2015

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane

July 15, 2014

Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.